risks of glp-1 drugs agonists and pancreatitis glp 1 Risk Updates in Medicine Risk pancreatic cancer associated – GLP-1 Agonists and Pancreatitis Risk

Supplement status does not permit medicinal claims

And GAS could block the mitogen-activated protein kinases (MAPK) signal pathway, and suppress the inflammatory mediators such as cyclic adenosine monophosphate (cAMP)-response element binding protein (CREB) and nuclear factor kappa-B (NF-B) phosphorylation, in PTZ-treated epileptic mice [35, 36]

Regulation of protein function by glutathionylation

These processes can potentiate the effects of other treatments by increasing tumor cell death and reducing resistance, particularly when apoptosis modulators are used in combination with chemotherapy

Vignoli A, Tenori L, Luchinat C, Saccenti E